Ponatinib attenuates experimental pulmonary arterial hypertension by modulating Wnt signaling and vasohibin-2/vasohibin-1.

@article{Kang2016PonatinibAE,
  title={Ponatinib attenuates experimental pulmonary arterial hypertension by modulating Wnt signaling and vasohibin-2/vasohibin-1.},
  author={Zechun Kang and Yunxia Ji and Guanghua Zhang and Yubei Qu and Liang Zhang and Wangling Jiang},
  journal={Life sciences},
  year={2016},
  volume={148},
  pages={1-8}
}
AIMS An abnormal ratio of vasohibin-2/vasohibin-1 may be involved in the abnormal angiogenesis and vascular remodeling during pulmonary arterial hypertension (PAH). MAIN METHODS To evaluate the pharmacological actions of Ponatinib (AP) in experimental model of PAH, the effects of AP on TGF-β1-mediated endothelial-mesenchymal transition (EndoMT) in human pulmonary microvascular endothelial cells (HPMEC), and the hypoxic human pulmonary artery smooth muscle cells (HPASMC) proliferation and… CONTINUE READING
Highly Cited
This paper has 23 citations. REVIEW CITATIONS

7 Figures & Tables

Topics

Statistics

0204020172018
Citations per Year

Citation Velocity: 14

Averaging 14 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.